LIFE Stock Overview
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Public Joint-Stock Company "Pharmsynthez" Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₽4.51 |
| 52 Week High | ₽7.00 |
| 52 Week Low | ₽2.65 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | 10.15% |
| 1 Year Change | -23.51% |
| 3 Year Change | -0.77% |
| 5 Year Change | -62.92% |
| Change since IPO | -81.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIFE | RU Pharmaceuticals | RU Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -2.4% |
| 1Y | -23.5% | 3.1% | 2.2% |
Return vs Industry: LIFE underperformed the Russian Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: LIFE exceeded the Russian Market which returned -38.2% over the past year.
Price Volatility
| LIFE volatility | |
|---|---|
| LIFE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in RU Market | 9.7% |
| 10% least volatile stocks in RU Market | 2.4% |
Stable Share Price: LIFE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LIFE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Petr Kurglyakov | www.pharmsynthez.com |
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez’ has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia.
Public Joint-Stock Company "Pharmsynthez" Fundamentals Summary
| LIFE fundamental statistics | |
|---|---|
| Market cap | ₽1.36b |
| Earnings (TTM) | -₽669.67m |
| Revenue (TTM) | ₽451.32m |
3.0x
P/S Ratio-2.0x
P/E RatioIs LIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIFE income statement (TTM) | |
|---|---|
| Revenue | ₽451.32m |
| Cost of Revenue | ₽244.37m |
| Gross Profit | ₽206.95m |
| Other Expenses | ₽876.62m |
| Earnings | -₽669.67m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | 45.85% |
| Net Profit Margin | -148.38% |
| Debt/Equity Ratio | 86.9% |
How did LIFE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/05 21:15 |
| End of Day Share Price | 2022/07/08 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Public Joint-Stock Company "Pharmsynthez" is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|